Unknown

Dataset Information

0

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.


ABSTRACT: The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches. In this study we evaluated the efficacy of a novel chemoimmunotherapeutic strategy to control HCC and investigated the underlying mechanism that increased the antitumor immune response. We developed a novel orthotopic mouse model of HCC through seeding of tumorigenic hepatocytes from SV40 T antigen (Tag) transgenic MTD2 mice into the livers of syngeneic C57BL/6 mice. These MTD2-derived hepatocytes form Tag-expressing HCC tumors specifically within the liver. This approach provides a platform to test therapeutic strategies and antigen-specific immune-directed therapy in an immunocompetent murine model. Using this model we tested the efficacy of a combination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor, and adoptive transfer of tumor antigen-specific CD8(+) T cells to eliminate HCC. Sunitinib treatment alone promoted a transient reduction in tumor size. Sunitinib treatment combined with adoptive transfer of tumor antigen-specific CD8(+) T cells led to elimination of established tumors without recurrence. In vitro studies revealed that HCC growth was inhibited through suppression of STAT3 signaling. In addition, sunitinib treatment of tumor-bearing mice was associated with suppression of STAT3 and a block in T-cell tolerance.These findings indicate that sunitinib inhibits HCC tumor growth directly through the STAT3 pathway and prevents tumor antigen-specific CD8(+) T-cell tolerance, thus defining a synergistic chemoimmunotherapeutic approach for HCC.

SUBMITTER: Avella DM 

PROVIDER: S-EPMC3243781 | biostudies-other | 2012 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications


<h4>Unlabelled</h4>The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches. In this study we evaluated the efficacy of a novel chemoimmunotherapeutic strategy to control HCC and investigated the underlying mechanism that increased the antitumor immune response. We developed a novel orthotopic mouse model of HCC through seeding of tumorigenic hepatocytes from SV40 T antigen (Tag) transgenic MTD2  ...[more]

Similar Datasets

| S-EPMC4800979 | biostudies-literature
| S-EPMC7481009 | biostudies-literature
| S-EPMC8084570 | biostudies-literature
| S-EPMC7757567 | biostudies-literature
| S-EPMC5064389 | biostudies-other
| S-EPMC3166282 | biostudies-literature
| S-EPMC9726717 | biostudies-literature
| S-EPMC6888677 | biostudies-literature
| S-EPMC6535757 | biostudies-literature
| S-EPMC6982125 | biostudies-literature